| Home : Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy |
|
Apr 06
2022 |
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy |
|
SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/innovent-announces-the-approval-of-pemazyre-pemigatinib-by-the-nmpa-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement-as-confirmed-by-a-vali |
| |
|
Related News
|
» Crononomics Comes in First for Gaming and Decentralized Applications on the Cronos Network
» Caesars Entertainment, Inc. Announces Revised Agreement to Sell William Hill Non-US Assets to 888 Holdings Plc
|
